Literature DB >> 20428776

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.

Maurizio Cianfriglia1, Alessandra Mallano, Alessandro Ascione, Maria Luisa Dupuis.   

Abstract

In this study we elucidated the role of ATP-binding cassette (ABC) multi-drug transporter proteins and cellular factors such as Bcl-2 expression and CD33 down-modulation contributing to free and hP67.6 mAb linked calicheamicin-gamma1 (CalC-gamma1) resistance. We analyzed in a well designed HL60 cell system the relationship between the expression of ABC proteins, Bcl-2 and CD33 modulation with the activity of free and mAb-linked CalC-gamma1. The results herein reported and discussed, strongly suggest that both MDR1-Pgp and MRP1 efflux systems are engaged by CalC-gamma1, but only MDR1-Pgp over-expression efficiently abrogates drug cytotoxicity in MDR cells. Paradoxically, Bcl-2 expression, as observed for other anticancer compounds belonging to the enediyne family of drugs, confers CalC-gamma1 susceptibility rather than resistance in HL60 cells. Further, the isolation of a resistant HL60 subline (HL60AL) that was developed by exposing the parental sensitive cells to sub-effective doses of gemtuzumab ozogamicin (GO) over an extended period of time shows a reduced level of CD33 expression that represents an important escape mechanism of HL60 MDR cells to the cytotoxic effect of GO.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428776     DOI: 10.3892/ijo_00000638

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.

Authors:  Colin D Godwin; Olivia M Bates; Sae Rin Jean; George S Laszlo; Eliotte E Garling; Mary E Beddoe; Michael H Cardone; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2020-07-04

Review 2.  Antibody-Based Treatment of Acute Myeloid Leukemia.

Authors:  Phillip M Garfin; Eric J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 3.  The clinical development of antibody-drug conjugates - lessons from leukaemia.

Authors:  Elias Jabbour; Shilpa Paul; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2021-03-23       Impact factor: 66.675

4.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

Review 5.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

6.  Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia.

Authors:  Bei Liu; Li-Jun Li; Xia Gong; Wei Zhang; Hui Zhang; Li Zhao
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

7.  In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.

Authors:  A Dutour; V Marin; I Pizzitola; S Valsesia-Wittmann; D Lee; E Yvon; H Finney; A Lawson; M Brenner; A Biondi; E Biagi; R Rousseau
Journal:  Adv Hematol       Date:  2012-01-05

Review 8.  CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.

Authors:  Francesco Lanza; Enrico Maffini; Michela Rondoni; Evita Massari; Angelo Corso Faini; Fabio Malavasi
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.